There are abundant evidences to support the beneficial effects of PPAR-γ activation against neurodegenerative diseases, including AD (45-48); however the electrophysiological mechanisms by which PPAR-γ activation prevents Aβ-induced functional alterations and the possibility of the use of its agonists at the early stages of AD have not been fully elucidated. This evidence concerns the gene PPARG and neurodegenerative disease.